Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline disease severity: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease
Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea
Objective: To assess the duration of rimabotulinumtoxinB action in the management of sialorrhea. Background: In neurological disorders, sialorrhea (drooling) is both prevalent and problematic. Local…Medical management of primary hemifacial spasm
Objective: The purpose of this study is to evaluate the effect of various anti-epileptic drugs(AED) in the medical management of HFS in patients who cannot…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study
Objective: This study aims to identify the reasons why people living with Parkinson’s disease (PD) (PwP) became involved with the PD STAT randomised controlled trial…BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease
Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Objective: To investigate efficacy and safety of two doses of Opicapone (OPC) compared to placebo administered once daily for 14 to 15 weeks to Japanese…Using cognitive computing to identify existing drugs with potential to stabilize mitophagy pathways associated with Parkinson’s Disease
Objective: We applied IBM Watson for Drug Discovery (WDD), a cognitive computing platform that uses natural language processing, to identify compounds with the potential to…
- « Previous Page
- 1
- …
- 54
- 55
- 56
- 57
- 58
- …
- 217
- Next Page »